Literature DB >> 1280802

Ibuprofen plus codeine, ibuprofen, and placebo in a single- and multidose cross-over comparison for coxarthrosis pain.

H Quiding1, J Grimstad, K Rusten, A Stubhaug, J Bremnes, H Breivik.   

Abstract

The analgesic efficacy of 200 mg ibuprofen plus 30 mg codeine, 200 mg ibuprofen and placebo was investigated in a new analgesic evaluation model using single- and repeated-dose administration. The study was a double-blind randomized cross-over investigation in 26 coxarthrosis patients with persistent pain. After a washout period of at least 2 days with paracetamol available as rescue analgesic, each of the 3 treatments was administered in a total of 6 doses during 24 h. The hourly pain intensity was recorded on a 100-mm visual analogue scale (VAS) for 8 h after the 1st and the 6th dose. The pretreatment VAS score was 31-37 mm. After the 1st dose the 8-h mean pain intensity values were 25, 27, and 26 mm after ibuprofen plus codeine, ibuprofen, and placebo, respectively. Following another 5 doses every 4 h the corresponding values were 10, 17 and 29 mm. Repeated administration of both active drugs reduced the pain intensity significantly. The analgesic efficacy of ibuprofen plus codeine was significantly superior to that of ibuprofen which was, in turn, superior to that of placebo. In conclusion, analgesic efficacy was better differentiated after repeated-dose than after single-dose administration. The present study design was able to differentiate between 200 mg ibuprofen plus 30 mg codeine and 200 mg ibuprofen alone in a relatively small number of patients.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1280802     DOI: 10.1016/0304-3959(92)90035-a

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  9 in total

1.  Osteoarthritis of the knee in primary care.

Authors:  Paul Dieppe
Journal:  BMJ       Date:  2007-12-04

Review 2.  A new role for opioids in the treatment of arthritis.

Authors:  Sanford H Roth
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 3.  Risk-benefit assessment of opioids in chronic noncancer pain.

Authors:  B Bannwarth
Journal:  Drug Saf       Date:  1999-10       Impact factor: 5.606

Review 4.  Ibuprofen: pharmacology, efficacy and safety.

Authors:  K D Rainsford
Journal:  Inflammopharmacology       Date:  2009-11-21       Impact factor: 4.473

Review 5.  Treatment of chronic pain in osteoarthritis: do opioids have a clinical role?

Authors:  A G Lipman
Journal:  Curr Rheumatol Rep       Date:  2001-12       Impact factor: 4.686

6.  Is There Any Role for Opioids in the Management of Knee and Hip Osteoarthritis? A Systematic Review and Meta-Analysis.

Authors:  Mikala C Osani; L Stefan Lohmander; Raveendhara R Bannuru
Journal:  Arthritis Care Res (Hoboken)       Date:  2021-09-01       Impact factor: 5.178

7.  Diclofenac does not interact with codeine metabolism in vivo: a study in healthy volunteers.

Authors:  Susanne Ammon; Claudia Marx; Christoph Behrens; Ute Hofmann; Thomas Mürdter; Ernst-Ulrich Griese; Gerd Mikus
Journal:  BMC Clin Pharmacol       Date:  2002-02-27

Review 8.  Multimodal Multidisciplinary Management of Patients with Moderate to Severe Pain in Knee Osteoarthritis: A Need to Meet Patient Expectations.

Authors:  Nicola Veronese; Cyrus Cooper; Olivier Bruyère; Nasser M Al-Daghri; Jaime Branco; Etienne Cavalier; Sara Cheleschi; Mario Coelho da Silva Rosa; Philip G Conaghan; Elaine M Dennison; Maarten de Wit; Antonella Fioravanti; Nicholas R Fuggle; Ida K Haugen; Gabriel Herrero-Beaumont; Germain Honvo; Andrea Laslop; Radmila Matijevic; Alberto Migliore; Ali Mobasheri; Jean-Pierre Pelletier; María Concepción Prieto Yerro; Régis Pierre Radermecker; François Rannou; René Rizzoli; Jean-Yves Reginster
Journal:  Drugs       Date:  2022-09-16       Impact factor: 11.431

9.  Long-term opioid treatment of chronic nonmalignant pain: unproven efficacy and neglected safety?

Authors:  Igor Kissin
Journal:  J Pain Res       Date:  2013-07-04       Impact factor: 3.133

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.